Targeted Systemic Gene Therapy and Molecular Imaging of Cancer. Contribution of the Vascular-Targeted AAVP Vector

Advances in Genetics

Volumn 69, Issue C, 2010, Pages 65-82

  Hajitou, Amin ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; VIRUS DNA; VIRUS RECEPTOR;

ADENO ASSOCIATED VIRUS; ANIMAL; BACTERIOPHAGE; DOG; DRUG EFFECT; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETICS; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; MOUSE; RAT; REVIEW; VASCULAR ENDOTHELIUM;

ANIMALS; BACTERIOPHAGES; DEPENDOVIRUS; DNA, VIRAL; DOGS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; MICE; MOLECULAR IMAGING; RATS; RECEPTORS, VIRUS; TRANSDUCTION, GENETIC;

EID: 77956156776     PISSN: 00652660     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0065-2660(10)69008-6     Document Type: Book

References (50)

1. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998, 279:377-380.
2. Arap W., Kolonin M.G., Trepel M., et al. Steps toward mapping the human vasculature by phage display. Nat. Med. 2002, 8:121-127.
3. Barrow P.A., Soothill J.S. Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential. Trends Microbiol. 1997, 5:268-271.
4. Bertoni C., Jarrahian S., Wheeler T.M., et al. Enhancement of plasmid mediated gene therapy for muscular dystrophy by directed plasmid integration. Proc. Natl. Acad. Sci. USA 2006, 103:419-424.
5. Bouard D., Alazard-Dany N., Cosset F.L. Viral vectors: From virology to transgene expression. Br. J. Pharmcol. 2009, 157:153-165.
6. vβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
7. Büning H., Perabo L., Coutelle O., et al. Recent developments in adeno-associated virus vector technology. J. Gene Med. 2008, 10:717-733.
8. Chatziioannou A.F. PET scanners dedicated to molecular imaging of small animal models. Mol. Imaging Biol. 2002, 4:47-63.
9. Chatziioannou A.F. Instrumentation for molecular imaging in preclinical research: Micro-PET and Micro-SPECT. Proc. Am. Thorac. Soc. 2005, 2(533-536):510-511.
10. vβ3 integrin. Mol. Cancer Res. 2004, 2:663-673.
11. Douglas J.T. Adenoviral vectors for gene therapy. Mol. Biotechnol. 2007, 36:71-80.
12. Duan D., Sharma P., Yang J., et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J. Virol. 1998, 72:8568-8577.
13. Ellerby H.M., Arap W., Ellerby L.M., et al. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 1999, 5:1032-1038.
14. Folkman J. Principles and Practice of Oncology. Cancer 1997, 3075-3085. Lippincott, Philadelphia. 5th edn. V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.).
15. Gambhir S.S., Bauer E., Black M.E., et al. A mutant herpes simplex virus type 1 thymidine kinase reporter gene shows improved sensitivity for imaging reporter gene expression with positron emission tomography. Proc. Natl. Acad. Sci. USA 2000, 97:2785-2790.
16. Gosh D., Barry M.A. Selection of muscle-binding peptides from context-specific peptide-presenting phage libraries for adenoviral vector targeting. J. Virol. 2005, 79:13667-13672.
17. Green N.K., Seymour L.W. Adenoviral vectors: Systemic delivery and tumor targeting. Cancer Gene Ther. 2002, 9:1036-1042.
18. Gregorevic P., Blankinship M.J., Allen J.M., et al. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 2004, 10:828-834.
19. Hajitou A., Pasqualini R., Arap W. Vascular targeting: Recent advances, and therapeutic perspectives. Trends Cardiovasc. Med. 2006, 16:80-88.
20. Hajitou A., Trepel M., Lilley C.E., et al. A hybrid vector for ligand-directed tumor targeting and molecular imaging. Cell 2006, 125:385-398.
21. Hajitou A., Rangel R., Trepel M., et al. Design and construction of targeted AAVP vectors for mammalian cell transduction. Nat. Protoc. 2007, 2:523-531.
22. Hajitou A., Levy D.C., Hannay J.A.F., et al. A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc. Natl. Acad. Sci. USA 2008, 105:4471-4476.
23. Hendrix R.W. Evolution: The long evolutionary reach of viruses. Curr. Biol. 1999, 9:R914-R917.
24. Hida K., Klagsburn M. A new perspective on tumor endothelial cells: Unexpected chromosome and centrosome abnormalities. Cancer Res. 2005, 65:2507-2510.
25. Hood J.D., Bednarski M., Frausto R., et al. Tumor regression by targeted gene delivery to the neovasculature. Science 2002, 296:2404-2407.
26. Jacobs A., Tjuvajev J.G., Dubrovin M., et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res. 2001, 61:2983-2995.
27. Juweid M.E., Cheson B.D. Positronemission tomography and assessment of cancer therapy. N. Engl. J. Med. 2006, 354:496-507.
28. Kanerva A., Zinn K.R., Peng K.W., et al. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus. Gene Ther. 2005, 12:87-94.
29. 3H]PCV for monitoring reporter gene expression of wild type and mutant Herpes simplex virus type 1 thymidine kinase in cell culture. Mol. Imaging Biol. 2005, 7:296-303.
30. Khuri F.R., Nemunaitis J., Ganly I., et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 2000, 6:879-885.
31. Larocca D., Witte A., Johnson W., et al. Targeting bacteriophage to mammalian cell surface receptors for gene delivery. Hum. Gene Ther. 1998, 9:2393-2399.
32. Marchiò S., Lahdenranta J., Schlingemann R.O., et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004, 5:151-162.
33. Meykadeh N., Mirmohammadsadegh A., Wang Z., et al. Topical application of plasmid DNA to mouse and human skin. J. Mol. Med. 2005, 83:897-903.
34. Nemunaitis J., Swisher S.G., Timmons T., et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J. Clin. Oncol. 2000, 18:609-622.
35. Oosterhoff D., Pinedo H.M., Witlox M.A., et al. Gene-directed enzyme prodrug therapy with carboxylesterase enhances the anticancer efficacy of the conditionally replicating adenovirus AdDelta24. Gene Ther. 2005, 12:1011-1018.
36. Paoloni M., Tandle A., Mazcko C., et al. Launching a Novel Preclinical Infrasturcture: Comparative Oncology Trials Consortium Directed Therapeutic Targeting of TNF-α to Cancer Vasculature. PLoS One 2009, 4:e4972.
37. Pasqualini R., Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996, 380:364-366.
38. Pasqualini R., Koivunen E., Kain R., et al. Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res. 2000, 60:722-727.
39. Peek R., Reddy K.R. FDA approves use of bacteriophages to be added to meat and poultry products. Gastroenterology 2006, 131:1370-1372.
40. Sadeghi H., Hitt M.M. Transcriptionally targeted adenovirus vectors. Curr. Gene Ther. 2005, 5:411-427.
41. Samulski R.J., Chang L.S., Shenk T. A recombinant plasmid from which an infectious adeno-associated virus genome can be excised in vitro and its use to study viral replication. J. Virol. 1987, 61:3096-3101.
42. Soghomonyan S., Doubrovin M., Pike J., et al. Positron emission tomography (PET) imaging of tumor-localized Salmonella expressing HSV1-TK. Cancer Gene Ther. 2005, 12:101-108.
43. Tandle A., Hanna E., Lorang D., et al. Tumor vasculature targeted delivery of tumor necrosis factor-alpha. Cancer 2009, 115:128-139.
44. Tjuvajev J.G., Finn R., Watanabe K., et al. Noninvasive imaging of herpes virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy. Cancer Res. 1996, 56:4087-4095.
45. Trepel M., Arap W., Pasqualini R. In vivo phage display and vascular heterogeneity: Implications for targeted medicine. Curr. Opin. Chem. Biol. 2002, 6:399-404.
46. Trepel M., Stoneham C.A., Eleftherohorinou H., et al. A heterotypic bystander effect for tumor cell killing after AAVP-mediated vascular targeted suicide gene transfer. Mol. Cancer Ther. 2009, 8:2383-2391.
47. Waehler R., Russell S.J., Curiel D.T. Engineering targeted viral vectors for gene therapy. Nat. Rev. Genet. 2007, 8:573-587.
48. Wang Z., Zhu T., Qiao C., et al. Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 2005, 23:321-328.
49. Wang Z., Kuhr C.S., Allen J.M., et al. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol. Ther. 2007, 15:1160-1166.
50. Weissleder R. Scaling down imaging: Molecular mapping of cancer in mice. Nat. Rev. Cancer 2002, 2:11-18.